Biomedical Engineering Reference
In-Depth Information
Table 10.1
In vitro
effi cacies of ester amide dendrimer conjugate and controls against balb/C
mice with C26 carcinoma [27].
Treatment
group
No. mice
Dose
(mg/kg)
Mean TGD
a)
(%)
Median
survival time
(days)
TRD
b)
LTS
PBS
c)
1 0
2 0
0
0
Doxil
10
20
245
b)
6 0
b)
2
8
229
b)
6 0
b)
27
10
20
0
9
27
10
15
175
b)
6 0
b)
0
6
74
c)
3 3
b)
27
10
10
0
1
a )
TGD, tumor growth delay, calculated from time of growth to 400 mm
3
.
b )
TRD, treatment-related death; LTS, long-term survivors. Compared to PBS,
P
≤
0.0001.
c )
Compared to PBS,
P
=
0.004. Compound
27
is represented in Scheme 10.10.
1. 0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0
10
20
30
40
50
60
Days after tumor inoculation
Figure 10.4
Representative survival probabil-
ity versus time in Balb/C mice bearing
subcutaneous C26 colon carcinoma after a
single injection of PEGylated poly(ester
amide) Dox conjugate or control. After tumor
generation, mice were treated for 8 days. [
27
(20 mg Dox equivalent/kg); 9,
27
(15 mg Dox equivalent/kg); 0,
27
(10 mg Dox equivalent/kg);
Δ
, Doxil
(20 mg Dox equivalent/kg); • , PBS [27] .]
The
in vitro
evaluation and
in vivo
tumor effi cacy of drug-loaded PEGylated ester
amide dendrimer have been described in details in Section 1.4 (Table 10.1 and
Figure 10.4 ).
10.4
Biological Implications of Biodegradable Dendrimers
After years of seeking to synthesize polymers in the form of long linear chains,
the attention has been focused on highly defi ned polymeric topologies, especially
